Ann Surg 2021 Jul 29. Epub 2021 Jul 29.
Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland Department of Surgery, University Hospital Erlangen, Erlangen, Germany Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland Department of Oncology, University Hospital Zurich, Zurich, Switzerland Department of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany Department of Surgery, Hospital Ansbach, Ansbach, Germany Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy Medical Oncology, IRCCS Azienda Ospedaliero, University of Bologna, Bologna, Italy Department of General, Visceral- and Transplantation Surgery, University Hospital Frankfurt am Main, Frankfurt, Germany Department of General and Transplantation Surgery, University Hospital Cologne, Köln, Germany Department of Digestive Surgery and Liver Transplantation, Croix Rousse University Hospital, University Lyon, Lyon, France Department of General, Visceral and Transplantation Surgery, University Hospital of Mainz, Mainz, Germany.
Objective: The aim of this study was to pool data from randomized controlled trials (RCT) limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a neoadjuvant therapy impacts on disease-free survival (DFS) and surgical outcome.Summary Background Data: Few underpowered studies have suggested benefits from neoadjuvant chemo (± radiation) for strictly resectable PDAC without offering conclusive recommendations.
Methods: Three RCTs were identified comparing neoadjuvant chemo (± radio) therapy vs. Read More